Oppenheimer & Co. is out with a research report on Clorox CLX and is downgrading the name to Perform from Outperform.
In a note to clients, Oppenheimer & Co. writes, "We are downgrading CLX to Perform from Outperform and suggest investors use Friday's strength and all-time high stock price to take profits on the heels of Carl Icahn's bid for the company (which is likely to be rejected, in our view). The shares are trading at a valuation not supported by fundamentals, and we are skeptical that a superior bid will materialize."
Shares of CLX closed at $74.55 on Friday.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorDowngradesPrice TargetAnalyst RatingsConsumer StaplesHousehold ProductsOppenheimer & Co.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in